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Abstract. Monoamine oxidases (MAOs) are amine oxidoreductase falvoenzymes that belong to the integral
proteins of the outer mitochondrial membrane. MAO exists in two distinct isoforms; MAO-A and MAO-B.
Inhibition of MAO-A and MAO-B is important for developing antidepressant and antiparkinson agents, respec-
tively. In the light of the above explanations, detailed structure binding relationship studies on the intermolec-
ular binding components of MAO-B complexes may unravel the way toward developing novel anti-Parkinson
agents. In the present contribution, intermolecular binding pattern for a series of experimentally validated
3-arylcoumarin MAO-B inhibitors (1–9) have been elucidated via molecular docking and density functional
theory (DFT) calculations. Intermolecular binding energy components could not be analyzed by docking and
due to this limitation, quantum mechanical (QM) calculations including functional B3LYP in association with
split valence basis set (Def2-SVP) were applied to estimate the ligand-residue binding energies in the MAO-
B active site. Moreover; results were interpreted in terms of calculated polarization effects that were induced
by individual amino acids of the MAO-B active site. The results of the present study provide an approach to
pharmacophore-based modification within the 3-arylcoumarin scaffold for potent MAO-B inhibitors.
Keywords. MAO-B; Coumarin; Molecular docking; Quantum mechanical calculation.
1. Introduction
Monoamine oxidases (MAOs) are amine oxidoreduc-
tase falvoenzymes that belong to the integral proteins
of the outer mitochondrial membrane.1 MAOs play
a vital role in the metabolism of important amines
in the central nervous system and peripheral tissues.2
Owing to the important role of MAOs in the metabolism
of monoamine neurotransmitters, MAO inhibitors are
used in the treatment of diverse neuropsychiatric and
neurological disorders.3,4
In mammals, MAO exists in two distinctive isoforms
that are identified as MAO-A and MAO-B. These two
isoforms differ in their amino acid sequence, substrate
specificity and sensitivity to selective inhibitors.5 Selec-
tive MAO-A inhibitors such as clorgyline are effective
antidepressant drugs, while selective MAO-B inhibitors
have been exploited as anti-Parkinson agents.6,7
MAO-B catalyzes the major catabolic pathway
(oxidative deamination) of β-phenylethylamines such
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as dopamine in the brain. MAO-B inhibitors boost the
dopaminergic neurotransmission as they prolong the
activity of dopamine in the brain and hence have been
used in the treatment of Parkinson’s disease.8 Selec-
tive MAO-B inhibitors such as Selegiline and Rasagi-
line have been applied as potential disease-modifying
agents in experimental clinical practice. It is impor-
tant to know that selective MAO-B inhibitors may alle-
viate some symptoms of the Parkinson’s disease such
as resting tremor but not have the therapeutic effect at
all.9 Considering this limitation, there is an urgent need
toward novel MAO-B inhibitors with less side effects
and higher potency.
Computer-aided drug discovery (CADD) is a ratio-
nal design technique with important beneficial features.
Proper application of CADD might lead to the reduced
time, energy and expenditure toward novel therapeu-
tic agents. CADD techniques are generally divided
into two major categories; ligand-based and receptor-
based methods. To run a receptor-based technique, 3D
structure of the macromolecular target should be in
hand. In this regard, available X-ray crystallographic
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structures of MAO (www.rcsb.org) provide an oppor-
tunity to elucidate the mechanisms of interactions
between MAO and MAO inhibitors (MAOIs). More-
over; exploring the ligand-receptor interactions unravel
the pharmacophoric requirements for designing potent
and selective MAOIs with therapeutic applications.
Coumarins are chemically classified as benzopyrone
derivatives with wide distribution in nature and bio-
logically interesting properties.10 Theses potentialities
introduced coumarins as privileged medicinal scaffolds
for drug design aims. In particular it has recently been
reported by several studies that 3-substituted coumarins
possess MAO-B inhibitory activity.11,12 A few reports
on docking study of 3-substituted coumarins may be
found in the literature.13,14 To provide additional in-
sights into the binding mode, molecular docking studies
of 3-phenylcoumarins (1–9) (scheme 1)5,15 were perfor-
med in the active site of MAO-B. Given the imperfec-
tion of docking simulations in providing the information
on intermolecular binding energy components,16 subse-
quent to the docking studies, we estimated the partici-
pation of each amino acid in total binding energy via an
Scheme 1. Chemical structures of 3-phenylcoumarins un-
der study (1-9).
amino acid decomposition analysis through a quantum
mechanical approach. In our opinion, such calcula-
tions are of significant importance in pharmacophore




Chemical structures of studied 3-phenylcoumarins
were taken from literature.5,15 Flexible-ligand docking
simulations were performed with AutoDock version
4.2.17 X-ray crystallographic structure of MAO-B was
retrieved from the Brookhaven protein data bank (1S2Q;
http://www.rcsb.org/). For preparation of a target pro-
tein, crystallographic ligand (Rasagiline) and water mo-
lecules were all removed from the original structure.
All the pre-processing steps for MAO-B file were
performed via WHAT IF server (http://swift.cmbi.ru.nl/
servers/html/prepdock.html/European Molecular Lab-
oratory Heidelberg, Germany) and AutoDock Tools
1.5.4 program (ADT).17,18 ADT program was used to
merge non-polar hydrogens into related carbon atoms
of the receptor and Kollman charges were also assigned.
For docked ligands, non-polar hydrogens were added;
Gasteiger charges assigned and torsions degrees of free-
dom were also considered by ADT program. Lamar-
ckian genetic algorithm (LGA) was applied to model
the interaction/binding between 3-phenylcoumarins and
MAO-B active site. On the basis of validation study
(represented in section 3), 100 GA runs; 27000 maxi-
mum generations; a gene mutation rate of 0.02; and a
crossover rate of 0.8 were used for LGA method.
MAO-B was characterized by grid maps in the actual
docking procedure. The grids were calculated using
AutoGrid module (part of the AutoDock package). The
grid included a map for each atom type in the ligand
and also a map for electrostatic interactions. A size of
grid was 60 × 60 × 60 Å3 (distributed in the x, y, and z
directions) and it was centered on the center of mass of
the catalytic site of MAO-B with a spacing of 0.375 Å.
Cluster analysis was performed on the docked results
with regard to RMS tolerance of 2 Å.
2.2 Ab initio studies
The contribution of individual amino acid-ligand inter-
action energies in total binding energy were estimated
using amino acid decomposition analysis (ADA). Amino
acids (residues) involved in binding of 3-phenylcou-
marin ligands to the MAO-B active site were chosen on
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the basis of previous reports on human MAO-B.19
For this purpose, all participating amino acids (Tyr60,
Phe168, Leu171, Cys172, Tyr188, Ile198, Ile199,
Gln206, Tyr326, Phe343, Tyr398 and Tyr435) along
with the flavin cofactor (flavin adenine dinucleotide:
FAD) were considered in their real electronic state. To
mimic the original electron density, all the residues
under study were truncated in their C and N termi-
nals. N-terminals were acetylated and C-terminals were
methyl amidated. All conformational and configura-
tional features were held as original X-ray structure.
One of the restrictions in such modeling studies is
the uncertainty of hydrogen positions in a typical X-
ray crystallographic file, and due to this limitation, we
further optimized the heavy atom hydrogen bonds by
B3LYP/ Def2-SVP method using heavy atom fixing
(HAF) approximation (constrained optimizations).20
All the interaction energies were estimated by the same
method and basis set. In energy calculations, long-
range dielectric effects of protein were considered using
COSMO model.21 The full calculations were done with
the ORCA quantum chemistry package.22
3. Results and Discussion
3.1 Molecular docking
Modern drug discovery strategies are dependent on
crystallographic 3D structural information of the rele-
vant biomolecular targets. Available X-ray crystallogra-
phic data on Protein Data Bank facilitated the structure
based design of various enzyme inhibitors. In this re-
gard, docking simulation is a key tool in structural mo-
lecular biology and computer-assisted drug design
(CADD). To explain more, the stereoelectronic fit of
ligand and receptor via lowest energy pathway may
be checked by docking simulations.23 Numerous suc-
cessful applications of molecular docking in drug dis-
covery efforts have been reported.24,25 One of the
most popular docking packages is AutoDock. Literature
review shows that AutoDock has offered several fruitful
advantages in the field of drug design (The AutoDock
website. http://autodock.scripps.edu).26
3.1.1 Docking validation step: To predict predomi-
nant binding mode of a cognate (co-crystallographic)
ligand,27 the structure of a cognate ligand was extracted
and re-docked into its receptor (self-docking). Suc-
cess is described in terms of comparison of root mean
square deviation (RMSD) of the Cartesian coordinates
of the atoms of the ligand in the docked and crystallo-
graphic conformations. A PDB-derived MAO-B struc-
ture including Rasagiline as cognate ligand (1S2Q) was
subjected to docking validation procedure. Selection
of the appropriate MAO-B structure was done on the
basis of crystallographic resolution and lack of missing
residues (http://www.rcsb.org/).
Regarding RMSD values and also conformation pop-
ulation in the top-ranked cluster of AutoDock output
file, we decided to run all of the docking simulations on
1S2Q structure as a validated crystallographic target for
MAO-B (table 1).
3.1.2 Binding mode and binding affinities: 3-phenyl-
coumarin structures (1–9) were all successfully docked
into the active site of MAO-B. Docking outputs were all
supported by high cluster populations. The results of the
docking simulation are summarized in table 2. For com-
parison, experimental inhibition constants were also
incorporated into table 2. All the MAO-B inhibitory
activities were retrieved from the in vitro measure-
ment of the enzymatic activity of human recombi-
nant MAO isoforms in BTI insect cells infected with
baculovirus.5,15
All the molecules under study shared a common
structural motif of 6-methylcoumarin while compounds
5-8 possessed a bromine substituent on the C8 position
of coumarin ring. Bearing this in mind, candidate
molecules were evaluated within two distinct groups
(C8-halogenated and C8-nonsubstituted) and for each
Table 1. Docking validation results for Rasagiline/MAO-B complex using AutoDock4.2.
Chemical Structure Maximum Population in RMSD from
PDB Resolution of cognate GA no. of energy the optimum reference
code (Å) ligand runs evaluations cluster (%) structure (Å)
1S2Q 2.07 100 2.5 × 106 91% 1.17
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Table 2. Docking simulations results for 3-phenylcouma-
rins in the active site of MAO-B.
AutoDock binding affinities (kcal/mol)
Final docked Estimated Free
Comp. pIC a50 energy Energy of Binding
1 7.884 −9.69 −9.09
2 9.097 −10.15 −9.56
3 Inactive −9.63 −9.03
4 6.808 −9.44 −8.85
5 7.957 −9.70 −9.40
6 8.491 −10.26 −9.67
7 8.148 −10.96 −10.07
8 5.311 −11.03 −9.83
9 5.367 −10.08 −9.78
aAll pIC50 values were calculated from the reported IC50s in
references.5,11
subclass, a prototype docked pose in the binding pocket
of MAO-B was explored (figures 1–3). Figure 3 repre-
sents a binding mode of 3-(2′-bromophenyl)-6-methyl-
cumarin (9) in the active site of MAO-B. For more clar-
ification, obtained binding poses of 3-phenylcoumarins
were compared with that of Rasagiline (figures 1–3).
The indan ring of Rasagiline is perpendicular to the
benzopteridinedione ring of FAD with the nearest posi-
tion to the central pyrazine ring. Detailed interaction
features of Rasagiline in the binding pocket of MAO-
B may be found elsewhere.28 Careful inspection of the
active site indicated that major binding contributions of
the inhibitors were lipophilic contacts via hydrophobic
residues of MAO-B. Similar results were also reported
for a series of 3-heteroarylcoumarin derivatives.13 It
should be emphasized that hydrophobic interactions are
composite in nature and their careful analysis in a sin-
gle model would face some inadequacies, but from the
least point of view, some aspects on active site oriented
pose of the ligand may be recognized via molecular
modeling approaches.
All 3-phenylcoumarins participated in H-bonding
with Cys172 via their coumarin carbonyl oxygen.
The coumarin ring in the docked molecules was ori-
ented a little closer to the Ile198, Ile199 and Cys172
when compared to Rasagiline. This new direction pro-
vided H-bonding with Cys172. 3-phenyl substituent of
coumarin ring in 1-9 was located between Tyr326 and
Ile199 residues making a π-π stacking interactions
with Tyr326.
Pursuing the activity profile of compounds 1-4
(table 2), it was revealed that para-methoxy (1) and
meta-methoxy (2) groups on 3-phenyl moiety of cou-
marin ring could be better tolerated than ortho-methoxy
groups (3). In this case, different observed activities
might be attributed to the possible steric clash between
C2′-substituted groups and Gln206. Such steric clashes
could be envisaged for weak MAO-B inhibitor 9 due to
the additional meta-substituted methoxy group. More-
over; superior activity of meta-methoxy substituted
Figure 1. Docking result of 3-(4′-Methoxyphenyl)-6-methylcumarin 1 (orange stick
model) with MAO-B (Rasagiline binding pose is presented by green stick model).
Molecular Modeling of MAO-B inhibitors 1215
Figure 2. Docking result of 8-bromo-3-phenyl-6-methylcumarin 5 (orange stick
model) with MAO-B (Rasagiline binding pose is presented by green stick model).
compound (2) could be the result of orientation towards
Phe168 residue and occupying this lipophilic cavity.
Similar trends might be presumed for the lower MAO-B
inhibitory activity of compound 9 (figure 3).
Lower MAO-B inhibitory activity of 4 indicated an
inappropriate orientation of para-hydroxy group in the
active site of MAO-B and in confirmation of this, our
obtained results showed no sign of H-bonding between
para-hydroxy moiety and MAO-B active site. None of
the modelled molecules were adequately close toward
Tyr435 and Tyr188 to make efficient lipophilic inter-
actions except compounds 5, 6, 7 and 8 bearing a
Figure 3. Docking result of 3-(2′-bromophenyl)-6-methylcumarin 9 (orange stick
model) with MAO-B (Rasagiline binding pose is presented by green stick model).
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bromine substituent on their C8 position of coumarin
ring (figure 2).
3.1.3 Regression analysis of docking affinities: None
of the AutoDock binding affinities (Estimated free
energy of binding and final intermolecular energy)
exhibited correlation with in vitro MAO-B inhibitory
activities. But a further regression analysis on the basis
of modified AutoDock binding energies (considering a
number of conformation clusters and top-ranked pop-
ulation in the AutoDock output file) led to enhanced
correlation with biological data (figure 4). To get the
detailed information on the proposed AutoDock bind-
ing energies, readers are referred to our previous report
in the field.29 In our opinion, modified AutoDock affini-
ties may provide a more rational design of MAO-B
inhibitors.
3.2 QM based binding energy analysis
Molecular docking is a well-established method to
achieve ligand-receptor binding patterns. In spite of
this feature, no information on individual ligand-amino
acid binding energies could be acquired upon docking.
Given this, we were convinced to estimate the bind-
ing energies of a prototype 3-phenylcoumarin derivative
with individual residues of the MAO-B binding site.
Similar binding energies for the complex of Rasagiline-
MAO-B were also calculated.
8-bromo-3-(3′, 5′-dimethoxyphenyl)-6-methylcuma-
rin (7) was selected as a model molecule for our QM
analysis since it possessed diverse substitution pattern
along with high in vitro MAO-B inhibitory activity
(IC50 = 7.12 nM).15 A model system including twelve
amino acids of the MAO-B active site (Tyr60, Phe168,
Leu171, Cys172, Tyr188, Ile198, Ile199, Gln206,
Tyr326, Phe343, Tyr398 and Tyr435) plus the FAD
Figure 4. Plot of modified AutoDock MAO-B binding
affinities versus in vitro MAO-B inhibitory activities for
studied 3-phenylcoumarin derivatives (1-9).
cofactor was constructed. Ligand-residue binding
energies (Eb) can be calculated by the Eq. (1):
Eb = ELR − ER − EL (1)
In the above equation, ELR is ligand-residue inter-
action energy, while ER and EL stand for the elec-
tronic energies of unbound residues and ligand, respec-
tively. Binding energies of compound 7 and Rasagi-
line with individual amino acid residues comprising the
MAO-B binding site at the B3LYP/ Def2-SVP level
of calculation are summarized in figures 5a and 5b,
respectively. It should be noted that all the calculations
of ligand-receptor energies were performed in the gas
phase without the involvement of desolvation energy in
the binding energy.
For compound 7, Cys172, Ile198 and Tyr398 were the
residues participated in H-bonding (−2.56 kcal/mol)
and lipophilic contacts (−2.56 and −1.72 kcal/mol)
to the ligand, respectively. One important point is
that the estimated binding energy for Cys172 might
not be exclusively translated into H-bond interaction
with Cys172 since sulfur is a weaker H-bond donor-
acceptor than oxygen or nitrogen. Moreover; our bind-
ing maps showed that the close orientation of Cys172
and compound 7 in the active site of MAO-B provided
more electrostatic interactions between compound 7
and backbone of Cys172. Such binding profile could
not be visualized for Rasagiline since it did not par-
ticipate in H-bond with Cys172. No attractive inter-
action energy could be estimated between Ile198 and
Rasagiline in B3LYP/ Def2-SVP level of calculation
(table 3). However our calculations showed that Rasag-
iline made slightly tighter contact to Tyr398 with regard
to compound 7.
The estimated binding energy for Tyr326 (table 3)
might be interpreted considering a π-π interaction
between relatively parallel phenyl rings of compound 7
and Tyr326 (figure 6).
Analysis of binding energies indicated that the inter-
action between FAD and compound 7 was supported with
higher binding energy (−1.94 kcal/mol) when compared
to the similar interaction with Rasagiline (−0.97 kcal/
mol) (table 3). Visualization of binding modes empha-
sized that extended lipophilic substituents on C6 and
C7 positions of coumarin ring might be desirable in
providing efficient interactions with FAD cofactor.
Binding energy estimations of compound 7 assigned
attractive interaction energy to the Phe168 residue
(−1.07 kcal/mol). This could to some extent indicate
a superior activity of meta-methoxy substituted com-
pounds (2 and 7) due to their orientation towards
Phe168. Binding cooperation for the interaction of com-
pound 7 and Tyr188 was found to be −0.66 kcal/mol
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Figure 5. Binding energies of (a) Rasagiline and (b) compound 7 with individual amino acid
residues of MAO-B binding pocket.
at the B3LYP/ Def2-SVP level of calculation. This rel-
atively weak attractive force might be attributed to the
bromine substituent on C8 position of coumarin ring.
Regarding the obtained results, it may be proposed that
incorporation of extended substituents including aro-
matic moieties would provide desirable lipophilic and
π-π stacking interactions with Tyr188 and Tyr435.
Major repulsive interactions between compound 7
and MAO-B active site were calculated for Leu171,
Phe343 and Ile199 (table 3). These repulsive forces
might be the direct outcome of inappropriate geometri-
cal poses with regard to Leu171 and Phe343 and Ile199.
According to the obtained results, Leu171 and Phe343
and Ile199 contacting groups of the ligand need to be
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Table 3. Mulliken Partial atomic charges for 8-bromo-3-(3′,5′-dimethoxyphenyl)-6 methylcumarin (Compound 7) induced
by various residues of MAO-B active site.
Atom type Free ligand Tyr60 Phe168 Leu171 Cys172 Ile198 Ile199 Gln206 Tyr326 Tyr398 Tyr435
C1 −0.099a 0.133 0.131 0.131 0.131 0.135 0.131 0.131 0.131 0.131 0.131
C2 0.092 −0.019 −0.020 −0.018 −0.018 −0.018 −0.018 −0.020 −0.020 −0.018 −0.018
C3 −0.160 0.022 0.023 0.023 0.023 0.022 0.022 0.023 0.023 0.023 0.023
C4 0.113 0.282 0.282 0.281 0.281 0.282 0.281 0.282 0.282 0.281 0.281
C5 −0.132 0.115 0.115 0.116 0.116 0.117 0.116 0.115 0.115 0.116 0.116
C6 0.075 −0.081 −0.081 −0.083 −0.082 −0.084 −0.082 −0.081 −0.080 −0.083 −0.082
C7 0.084 −0.018 −0.015 −0.014 −0.014 −0.018 −0.014 −0.014 −0.015 −0.014 −0.014
O8 −0.136 −0.499 −0.499 −0.499 −0.499 −0.498 −0.499 −0.499 −0.499 −0.499 −0.499
C9 0.400 0.550 0.549 0.550 0.549 0.550 0.550 0.550 0.550 0.550 0.550
C10 −0.120 −0.013 −0.014 −0.013 −0.013 −0.013 −0.013 −0.013 −0.013 −0.013 −0.013
C11 0.119 0.003 0.004 0.003 0.002 0.003 0.002 0.003 0.003 0.003 0.003
O12 −0.125 −0.465 −0.466 −0.466 −0.465 −0.466 −0.466 −0.465 −0.466 −0.465 −0.466
Br13 0.060 −0.082 −0.083 −0.082 −0.082 −0.081 −0.082 −0.082 −0.082 −0.082 −0.082
C14 0.027 0.076 0.082 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076
C15 −0.060 −0.052 −0.070 −0.052 −0.052 −0.051 −0.051 −0.052 −0.052 −0.052 −0.052
C16 0.126 0.323 0.339 0.323 0.323 0.319 0.316 0.323 0.323 0.323 0.323
C17 −0.127 −0.048 −0.092 −0.048 −0.049 −0.046 −0.045 −0.048 −0.048 −0.048 −0.048
C18 0.132 0.302 0.336 0.302 0.302 0.302 0.303 0.302 0.302 0.302 0.302
C19 −0.008 0.002 −0.017 0.001 0.002 0.001 0.002 0.002 0.002 0.002 0.002
O20 −0.191 −0.533 −0.527 −0.533 −0.533 −0.530 −0.531 −0.533 −0.533 −0.533 −0.533
C21 0.158 0.270 0.270 0.270 0.270 0.268 0.271 0.270 0.270 0.270 0.270
O22 −0.180 −0.531 −0.515 −0.531 −0.531 −0.529 −0.532 −0.531 −0.531 −0.531 −0.531
C23 0.155 0.262 0.268 0.262 0.262 0.259 0.262 0.262 0.262 0.262 0.262
aAtomic charges with hydrogens summed into heavy atoms.
Figure 6. 3D schematic representation of a π -π interaction
between relatively parallel phenyl rings of compound 7 and
Tyr326 in the MAO-B binding site.
well decorated in future designs of MAO-B blocking
3-phenylcoumarins.
3.3 Induced polarizability
Stereoelectronic contributions are very important in
ligand-receptor interactions. The binding orientation of
the ligand in the active site of a receptor is determined
by the complementary fitness between electronic and
steric surfaces of ligand and receptor. A part of stere-
oelectronic effect may be interpreted as ligand polar-
izability which is induced by different residues of the
active site. For this purpose, induced ligand polarizabil-
ities in terms of partial atomic charges for compound 7
were estimated.30
Ligand polarizability can be defined as the differ-
ence between partial charges in the bound and unbound
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states of a typical enzyme inhibitor. The larger induced
polarizability value indicates higher participation of
electrostatic interactions in binding of amino acid to
the ligand. The relevant induced polarization effects are
summarized in table 3. For more clarification, despite
the similarity of partial charges in the case of various
amino acids, all the data were incorporated.
Careful inspection of the data indicated that large
polarization effects occurred at atomic positions
attributed to key electrostatic interactions (O8, O12,
O20 and O22) while C15 and C19 atoms tolerated the
least electrostatic changes (table 3) showing their buried
orientation at the active site of MAO-B. An important
point to note is that hydrophobic forces are also electro-
static in nature since they are caused by correlations in
the fluctuating polarizations of nearby particles.
The resultant polarization effects might also be eluci-
dated in terms of induced negative or positive electronic
effects. Electronegative atoms O8, O12, Br13, O20 and
O22 accept negative induced effect in the binding cav-
ity of MAO-B indicating their contribution to the elec-
trostatic interactions with corresponding amino acids.
Other atoms bearing negative induced effect are C2, C6,
C7 and C11.
4. Conclusions
A series of experimentally tested 3-phenylcoumarin
MAO-B inhibitors were elucidated for their inter-
molecular binding interaction with recombinant human
MAO-B enzyme via docking/QM methods. The results
were in logical accordance with previous data in the
literature. Structure activity relationship (SAR) stud-
ies indicated that coumarin ring may be a good sub-
stitution pattern for indan ring of Rasagiline in bind-
ing to the MAO-B active site. 3-(ortho-methoxyphenyl)
substituted coumarins might not be appropriate phar-
macophores for MAO-B inhibition while 3-(meta-
methoxyphenyl) substituted ones can be regarded as
suitable choices. Aromatic rings substituted at C3 of
coumarin ring might take part in π-π interactions with
Tyr326 via their semi-parallel orientation towards the
phenyl ring of Tyr326. Incorporation of 8-halo sub-
stituent to the coumarin ring might provide additional
electrostatic/lipophilic contact with Tyr188. It seemed
that the existence of 6-alkyl moieties afforded a suitable
scaffold to make efficient interactions with FAD cofac-
tor of MAO-B binding site. Our results indicated that
analysis of intermolecular binding energies between
ligand and various constituents of the active site may
be a complementary approach to docking simula-
tions in achieving MAO-B inhibitory pharmacophores.
Furthermore, induced polarizabilities of ligand in the
active site of the enzyme might give an idea about the
exposed or buried parts of the ligand in the MAO-B
binding pocket. The outcomes of this study might be
useful in developing structure binding relationship of
some coumarin derivatives with the aim of achieving
potent small molecule MAO-B inhibitors.
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